The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Uterine Hemorrhage

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Uterine Hemorrhage


High impact information on Uterine Hemorrhage

  • Uterine bleeding, and hence the diagnosis of otherwise asymptomatic cancer, cannot be attributed to estrogen use that ceased in the distant past [6].
  • Women on chronic tamoxifen therapy should have routine annual gynecologic examinations and receive endometrial sampling only in the event of uterine bleeding [7].
  • Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression [8].
  • Abnormal uterine bleeding after Norplant administration is primarily responsible for the high discontinuation rate of this safe and effective long-acting implantable progestin-only contraceptive agent [9].
  • A modest rebound in TF mRNA and protein expression was observed after 12 months of Norplant therapy, which occurred commensurate with reduced patient complaints of abnormal uterine bleeding [10].

Chemical compound and disease context of Uterine Hemorrhage

  • Collapse of the dominant follicle was evident on ultrasound after RU486 administration and was not accompanied by uterine bleeding [11].
  • Corpus luteum rescue with incremental doses of hCG did not prevent uterine bleeding after RU486 treatment [12].
  • These values also correlate well with values for the apparent rate of production of estrone in our 9 patients and also in 5 postomenopausal patients with uterine bleeding reported in the literature, but no such correlation is evident for postmenopausal women without endometrial abnormality reported in the literature [13].
  • The results indicate that an increased local production of prostacyclin (PGI2) relative to thromboxane A2 at the time of menstruation could contribute to the mechanism of uterine bleeding [14].
  • Tibolone was effective in the treatment of climacteric symptoms, and only 8.7% of the participants presented uterine bleeding during treatment [15].

Biological context of Uterine Hemorrhage


Anatomical context of Uterine Hemorrhage


Gene context of Uterine Hemorrhage


Analytical, diagnostic and therapeutic context of Uterine Hemorrhage


  1. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Diem, S., Grady, D., Quan, J., Vittinghoff, E., Wallace, R., Hanes, V., Ensrud, K. Menopause (New York, N.Y.) (2006) [Pubmed]
  2. Estrogen production and action. Nelson, L.R., Bulun, S.E. J. Am. Acad. Dermatol. (2001) [Pubmed]
  3. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Anania, C.A., Stewart, E.A., Quade, B.J., Hill, J.A., Nowak, R.A. Mol. Hum. Reprod. (1997) [Pubmed]
  4. Hydatidiform mole and gestational trophoblastic disease in Southern Connecticut. Kohorn, E.I. Obstetrics and gynecology. (1982) [Pubmed]
  5. Female gonorrhea: its relation to abnormal uterine bleeding, urinary tract symptoms, and cervicitis. Curran, J.W., Rendtorff, R.C., Chandler, R.W., Wiser, W.L., Robinson, H. Obstetrics and gynecology. (1975) [Pubmed]
  6. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. Shapiro, S., Kaufman, D.W., Slone, D., Rosenberg, L., Miettinen, O.S., Stolley, P.D., Rosenshein, N.B., Watring, W.G., Leavitt, T., Knapp, R.C. N. Engl. J. Med. (1980) [Pubmed]
  7. Does tamoxifen cause cancer in humans? Stearns, V., Gelmann, E.P. J. Clin. Oncol. (1998) [Pubmed]
  8. Abnormal uterine bleeding during progestin-only contraception may result from free radical-induced alterations in angiopoietin expression. Krikun, G., Critchley, H., Schatz, F., Wan, L., Caze, R., Baergen, R.N., Lockwood, C.J. Am. J. Pathol. (2002) [Pubmed]
  9. Effects of norplant on endometrial tissue factor expression and blood vessel structure. Runic, R., Schatz, F., Wan, L., Demopoulos, R., Krikun, G., Lockwood, C.J. J. Clin. Endocrinol. Metab. (2000) [Pubmed]
  10. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception. Runic, R., Schatz, F., Krey, L., Demopoulos, R., Thung, S., Wan, L., Lockwood, C.J. J. Clin. Endocrinol. Metab. (1997) [Pubmed]
  11. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486. Liu, J.H., Garzo, G., Morris, S., Stuenkel, C., Ulmann, A., Yen, S.S. J. Clin. Endocrinol. Metab. (1987) [Pubmed]
  12. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. Garzo, V.G., Liu, J., Ulmann, A., Baulieu, E., Yen, S.S. J. Clin. Endocrinol. Metab. (1988) [Pubmed]
  13. Production of estrone and fractional conversion of circulating androstenedione to estrone in women with endometrial carcinoma. Rizkallah, T.H., Tovell, H.M., Kelly, W.G. J. Clin. Endocrinol. Metab. (1975) [Pubmed]
  14. 6-oxo-prostaglandin F1 alpha and thromboxane B2 in uterine vein blood--a possible role in menstrual bleeding. Goodfellow, C.F., Paton, R.C., Salmon, J.A., Moncada, S., Clayton, J.K., Davies, J.A., McNicol, G.P. Thromb. Haemost. (1982) [Pubmed]
  15. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Wender, M.C., Edelweiss, M.I., Campos, L.S., de Castro, J.A., Spritzer, P.M. Menopause (New York, N.Y.) (2004) [Pubmed]
  16. The late pubertal cascade in perimenarchial monkeys: onset of asymmetrical ovarian estradiol secretion and bioassayable luteinizing hormone release. Williams, R.F., Turner, C.K., Hodgen, G.D. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  17. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach. Lemay, A., Faure, N. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  18. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Chegini, N., Rhoton-Vlasak, A., Williams, R.S. Fertil. Steril. (2003) [Pubmed]
  19. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Hargrove, J.T., Maxson, W.S., Wentz, A.C., Burnett, L.S. Obstetrics and gynecology. (1989) [Pubmed]
  20. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Schatz, F., Kuczynski, E., Kloosterboer, H.J., Buchwalder, L., Tang, C., Krikun, G., Lockwood, C.J. Steroids (2005) [Pubmed]
  21. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Vincent, A.J., Salamonsen, L.A. Hum. Reprod. (2000) [Pubmed]
  22. Intrauterine irrigation with prostaglandin F2-alpha for management of severe postpartum hemorrhage. Kupferminc, M.J., Gull, I., Bar-Am, A., Daniel, Y., Jaffa, A., Shenhav, M., Lessing, J.B. Acta obstetricia et gynecologica Scandinavica. (1998) [Pubmed]
  23. Adenomyosis demonstrates increased expression of the basic fibroblast growth factor receptor/ligand system compared with autologous endometrium. Propst, A.M., Quade, B.J., Gargiulo, A.R., Nowak, R.A., Stewart, E.A. Menopause (New York, N.Y.) (2001) [Pubmed]
  24. Elevation of insulin-like growth factor-binding protein-1 mRNA expression following hormone replacement therapy. Wang, H.S., Wang, T.H., Soong, Y.K. Hum. Reprod. (2000) [Pubmed]
  25. Role of nitric oxide in implantation and menstruation. Chwalisz, K., Garfield, R.E. Hum. Reprod. (2000) [Pubmed]
  26. Role of EBAF/Lefty in implantation and uterine bleeding. Tabibzadeh, S. Ernst Schering Res. Found. Workshop (2005) [Pubmed]
  27. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Weeks, A.D., Duffy, S.R., Walker, J.J. Am. J. Obstet. Gynecol. (1999) [Pubmed]
  28. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Al-Azzawi, F., Wahab, M., Thompson, J., Whitehead, M., Thompson, W. Hum. Reprod. (1999) [Pubmed]
  29. Differential diagnosis of abnormal uterine bleeding. Brenner, P.F. Am. J. Obstet. Gynecol. (1996) [Pubmed]
  30. Hormonal variations in secondary amenorrhoea during the metyrapone test. Mazzi, C., Riva, L.P., Bernasconi, D. Clin. Endocrinol. (Oxf) (1976) [Pubmed]
  31. The treatment of uterine bleeding with vasopressin hormonogen (glypressin)--a pilot study. Pavlín, V., Flynn, M.J., Mulder, J.L., Cort, J.H. British journal of obstetrics and gynaecology. (1978) [Pubmed]
WikiGenes - Universities